« Back to Vicor Press Releases
Contact:
David H. Fater
President and Chief Executive Officer
(800) 998-9964
Mark E. Josephson, M.D. Joins Scientific Advisory Board
BOCA RATON, FLORIDA — January 19, 2004 — VICOR TECHNOLOGIES, INC. ("Vicor" or "the Company") today announced Mark E. Josephson, M.D. has joined Vicor's Scientific Advisory Board.
Mark Josephson, M.D. is a graduate of Trinity College and Columbia University College of Physicians and Surgeons, Class of 1969. He completed his Residency Training at Mount Sinai Hospital in New York, and Fellowship Training in Cardiology at the University of Pennsylvania School of Medicine. Dr. Josephson is currently the chief of the division of cardiology at Beth Israel Deaconess Medical Center, a major patient care, research and teaching affiliate of Harvard Medical School. His research in the areas of electrophysiology is reported in more than 300 original publications and 200 chapters/reviews and editorials. Dr. Josephson is credited with developing the field of Clinical Cardiac Electrophysiology from an intellectual curiosity to a powerful diagnostic and therapeutic tool for the management of arrhythmias. Dr. Josephson single-authored textbook, Clinical Cardiac Electrophysiology, is the fundamental textbook in the field.
Commenting on the relationship, David H. Fater, President and Chief Executive Officer of Vicor said, "We are extremely pleased and delighted to have a renowned electrophysiologist with Dr. Josephson's background and credentials join our Scientific Advisory Board. His clinical knowledge and perspective will be vitally important as we commercialize the Vicor PD2i Cardiac Analyzer once FDA clearance has been obtained."
Vicor Technologies, Inc. is a biotechnology company dedicated to the development of breakthrough diagnostic and therapeutic products. The Company's diagnostics products are based on the Company's patented PD2i algorithm, which is used to predict future pathological events, specifically but not limited to, fatal cardiac arrhythmic death, Mad Cow Disease, and a number of other high profile diagnostic indications. Vicor's therapeutic products have been developed by using an innovative drug discovery platform which focuses on naturally occurring biomolecules derived from state-dependent physiologies such as hibernation.
Certain statements contained herein are "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
Vicor Technologies, Inc., prepared this update and is solely responsible for its content.